Alira Health

Alira Health

AseBio and Alira Health Partner to Foster Market Access for Biotech Startups

News
Published on:
September 27, 2022

Alira Health, a global healthcare advisory and technology company, and AseBio, the Spanish Bioindustry Association, are joining forces to support Spanish biotech companies looking to enter new markets.

Together, AseBio and Alira Health will provide a market access mentoring program for AseBio members to promote access to innovation.

Alira Health, a member of AseBio since Spring 2022, will pair its experienced market access consultants with companies to improve their value proposition, navigate the ecosystem, and properly define their market access needs. The program features a 40-hour service package that includes an initial meeting, background analysis, tailored orientation session for market access and pricing, and gap analysis.

It is a pleasure for us as Alira Health to collaborate with AseBio in this mentoring program. We hope that this will allow us to help biotech companies have better access to the market, and in addition, train companies in areas where they need development.”
Chus Castillo Vice President, Market Access, Alira Health (Iberia)

The program will start in November 2023, and application is open to all AseBio SMEs. Three companies will be selected for the inaugural program.

Ion Arocena, General Director at AseBio, and Chus Castillo, Vice President of Market Access at Alira Health (Iberia), attended the signing event.

“It is a pleasure for us as Alira Health to collaborate with AseBio in this mentoring program. We hope that this will allow us to help biotech companies have better access to the market, and in addition, train companies in areas where they need development”, says Chus Castillo, Vice President of Market Access at Alira Health (Iberia).

Would you like to learn more about Alira Health’s partnership with AseBio? Watch this interview with our team.

Related news

Articles July 4, 2024
Navigating Market Access for Rare Diseases: The Potential of Real-World Evidence
Our experts answer common questions about the strategic need for real-world evidence to drive market access for rare diseases.
Market Access Rare Disease Real-World Evidence (RWE)
Case Studies July 2, 2024
European Biotech Builds a Strategy for a Radioligand Therapy in Metastatic Prostate Cancer
A biotech specializing in radioligand therapies wanted to understand the opportunity to capture a relevant market share of the metastatic prostate cancer space.
Biotech Nuclear Medicine Oncology
Case Studies June 27, 2024
A Multinational Pharma Targeting Myasthenia Gravis Garners Payer Advice on Market Access
Our client sought to incorporate early payer advice on the MG clinical trial design, identify evidence gaps, and provide insights on the overall development program for the asset.
Market Access Myasthenia Gravis (MG) Rare Disease
Events April 22, 2024
Biotech CEO Summit
We will sponsor and attend the 2024 Biotech CEO Summit. Connect with our EVP of Biopharma, Joris Pezzini, onsite in Barcelona.
Biopharma Biotech
Events March 25, 2024
Swiss Biotech Day 2024
We will sponsor, attend, and speak at Swiss Biotech Day. Don't miss our panel on strengthening ties to investors in uncertain times.
Biotech
Articles March 18, 2024
WHO Model Lists of Essential Medicines: What You Need to Know 
Our Market Access experts share the importance of the EML for pharma companies and four best practices for a successful application, based on our extensive experience in interactions with the WHO.
Market Access
Events February 22, 2024
Bio-Europe Spring
Connect with our biotech experts onsite in Barcelona at Bio-Europe Spring. How can we support your development plan and funding path?
Biotech
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.